1
|
Yu R, Hao F, Zhang X, Fang Z, Jin Z, Liu G, Dai G, Wu J. Cobalt-Catalyzed Chemoselective Reduction of N-Heteroaryl Ketones with N, N-Dimethylformamide as a Hydride Source. J Org Chem 2023. [PMID: 37257025 DOI: 10.1021/acs.joc.3c00283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
A method for chemoselective reduction of 2-pyridyl ketones and related N-heteroaryl compounds catalyzed by cobalt stearate using DMF as a hydride source is developed. The ketone substrate is activated by chelation with cobalt, which makes the present method highly chemoselective. A possible reaction mechanism is proposed on the basis of control experiments.
Collapse
Affiliation(s)
- Rurong Yu
- School of Pharmaceutical and Chemical Engineering, Taizhou University, Jiaojiang 318000, China
| | - Feiyue Hao
- School of Pharmaceutical and Chemical Engineering, Taizhou University, Jiaojiang 318000, China
| | - Xinyu Zhang
- School of Pharmaceutical and Chemical Engineering, Taizhou University, Jiaojiang 318000, China
| | - Zhongbing Fang
- School of Pharmaceutical and Chemical Engineering, Taizhou University, Jiaojiang 318000, China
| | - Zhengneng Jin
- School of Pharmaceutical and Chemical Engineering, Taizhou University, Jiaojiang 318000, China
| | - Guyue Liu
- School of Pharmaceutical and Chemical Engineering, Taizhou University, Jiaojiang 318000, China
| | - Guoliang Dai
- School of Chemical Biology and Materials Engineering, Suzhou University of Science and Technology, Suzhou 215009, China
| | - Jiashou Wu
- School of Pharmaceutical and Chemical Engineering, Taizhou University, Jiaojiang 318000, China
| |
Collapse
|
2
|
Ramachanderan R, Schramm S, Schaefer B. Migraine drugs. CHEMTEXTS 2023. [DOI: 10.1007/s40828-023-00178-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023]
Abstract
AbstractAccording to recent studies, migraine affects more than 1 billion people worldwide, making it one of the world’s most prevalent diseases. Although this highly debilitating illness has been known since ancient times, the first therapeutic drugs to treat migraine, ergotamine (Gynergen) and dihydroergotamine (Dihydergot), did not appear on the market until 1921 and 1946, respectively. Both drugs originated from Sandoz, the world’s leading pharmaceutical company in ergot alkaloid research at the time. Historically, ergot alkaloids had been primarily used in obstetrics, but with methysergide (1-methyl-lysergic acid 1′-hydroxy-butyl-(2S)-amide), it became apparent that they also held some potential in migraine treatment. Methysergide was the first effective prophylactic drug developed specifically to prevent migraine attacks in 1959. On the basis of significantly improved knowledge of migraine pathophysiology and the discovery of serotonin and its receptors, Glaxo was able to launch sumatriptan in 1992. It was the first member from the class of triptans, which are selective 5-HT1B/1D receptor agonists. Recent innovations in acute and preventive migraine therapy include lasmiditan, a selective 5-HT1F receptor agonist from Eli Lilly, the gepants, which are calcitonin gene-related peptide (CGRP) receptor antagonists discovered at Merck & Co and BMS, and anti-CGRP/receptor monoclonal antibodies from Amgen, Pfizer, Eli Lilly, and others.
Graphical abstract
Collapse
|
3
|
Flick AC, Leverett CA, Ding HX, McInturff EL, Fink SJ, Mahapatra S, Carney DW, Lindsey EA, DeForest JC, France SP, Berritt S, Bigi-Botterill SV, Gibson TS, Watson RB, Liu Y, O'Donnell CJ. Synthetic Approaches to the New Drugs Approved During 2020. J Med Chem 2022; 65:9607-9661. [PMID: 35833579 DOI: 10.1021/acs.jmedchem.2c00710] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
New drugs introduced to the market are privileged structures that have affinities for biological targets implicated in human diseases and conditions. These new chemical entities (NCEs), particularly small molecules and antibody-drug conjugates (ADCs), provide insight into molecular recognition and simultaneously function as leads for the design of future medicines. This Review is part of a continuing series presenting the most likely process-scale synthetic approaches to 44 new chemical entities approved for the first time anywhere in the world during 2020.
Collapse
Affiliation(s)
- Andrew C Flick
- Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Carolyn A Leverett
- Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Hong X Ding
- Pharmacodia (Beijing) Co. Ltd., Beijing 100085, China
| | - Emma L McInturff
- Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Sarah J Fink
- Takeda Pharmaceuticals, 125 Binney Street, Cambridge, Massachusetts 02142, United States
| | - Subham Mahapatra
- Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Daniel W Carney
- Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Erick A Lindsey
- Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Jacob C DeForest
- Pfizer Worldwide Research and Development, La Jolla Laboratories, 10777 Science Center Drive, San Diego, California 92121, United States
| | - Scott P France
- Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Simon Berritt
- Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | | | - Tony S Gibson
- Takeda Pharmaceuticals, 9625 Towne Centre Drive, San Diego, California 92121, United States
| | - Rebecca B Watson
- Pfizer Worldwide Research and Development, La Jolla Laboratories, 10777 Science Center Drive, San Diego, California 92121, United States
| | - Yiyang Liu
- Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| | - Christopher J O'Donnell
- Pfizer Worldwide Research and Development, Groton Laboratories, 445 Eastern Point Road, Groton, Connecticut 06340, United States
| |
Collapse
|
4
|
Yu Y, Liu A, Dhawan G, Mei H, Zhang W, Izawa K, Soloshonok VA, Han J. Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity. CHINESE CHEM LETT 2021. [DOI: 10.1016/j.cclet.2021.05.042] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
5
|
Liu A, Han J, Nakano A, Konno H, Moriwaki H, Abe H, Izawa K, Soloshonok VA. New pharmaceuticals approved by FDA in 2020: Small-molecule drugs derived from amino acids and related compounds. Chirality 2021; 34:86-103. [PMID: 34713503 DOI: 10.1002/chir.23376] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2021] [Revised: 09/09/2021] [Accepted: 09/26/2021] [Indexed: 12/24/2022]
Abstract
Amino acids (AAs) play an important role in the modern health industry as key synthetic precursors for pharmaceuticals, biomaterials, biosensors, and drug delivery systems. Currently, over 30% of small-molecule drugs contain residues of tailor-made AAs or derived from them amino-alcohols and di-amines. In this review article, we profile 12 AA-derived new pharmaceuticals approved by the FDA in 2020. These newly introduced drugs include Tazverik (epithelioid sarcoma), Gemtesa (overactive bladder), Zeposia (multiple sclerosis), Byfavo (induction and maintenance of procedural sedation), Cu 64 dotatate, and Gallium 68 PSMA-11 (both PET imaging), Rimegepant (acute migraine), Zepzelca (lung cancer), Remdesivir (COVID-19), Amisulpride (nausea and vomiting), Setmelanotide (obesity), and Lonafarnib (progeria syndrome). For each compound, we describe the spectrum of biological activity, medicinal chemistry discovery, and synthetic preparation.
Collapse
Affiliation(s)
- Aiyao Liu
- Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China
| | - Jianlin Han
- Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, China
| | - Arina Nakano
- Department of Biological Engineering, Graduate School of Science and Engineering, Yamagata University, Yonezawa, Japan
| | - Hiroyuki Konno
- Department of Biological Engineering, Graduate School of Science and Engineering, Yamagata University, Yonezawa, Japan
| | | | | | | | - Vadim A Soloshonok
- Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, San Sebastián, Spain.,IKERBASQUE, Basque Foundation for Science, Bilbao, Spain
| |
Collapse
|
6
|
Seo CSG, Tsui BTH, Gradiski MV, Smith SAM, Morris RH. Enantioselective direct, base-free hydrogenation of ketones by a manganese amido complex of a homochiral, unsymmetrical P–N–P′ ligand. Catal Sci Technol 2021. [DOI: 10.1039/d1cy00446h] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Base-free direct hydrogenation of ketones using a Mn(PNP′)(CO)2 complex is more enantioselective than that of a related base-activated iron complex.
Collapse
|
7
|
Lebedev Y, Polishchuk I, Maity B, Dinis Veloso Guerreiro M, Cavallo L, Rueping M. Asymmetric Hydroboration of Heteroaryl Ketones by Aluminum Catalysis. J Am Chem Soc 2019; 141:19415-19423. [DOI: 10.1021/jacs.9b10364] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Yury Lebedev
- King Abdullah University of Science and Technology (KAUST) KAUST Catalysis Center (KCC), Thuwal 23955-6900, Saudi Arabia
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, Aachen 52074, Germany
| | - Iuliia Polishchuk
- King Abdullah University of Science and Technology (KAUST) KAUST Catalysis Center (KCC), Thuwal 23955-6900, Saudi Arabia
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, Aachen 52074, Germany
| | - Bholanath Maity
- King Abdullah University of Science and Technology (KAUST) KAUST Catalysis Center (KCC), Thuwal 23955-6900, Saudi Arabia
| | - Miguel Dinis Veloso Guerreiro
- King Abdullah University of Science and Technology (KAUST) KAUST Catalysis Center (KCC), Thuwal 23955-6900, Saudi Arabia
| | - Luigi Cavallo
- King Abdullah University of Science and Technology (KAUST) KAUST Catalysis Center (KCC), Thuwal 23955-6900, Saudi Arabia
| | - Magnus Rueping
- King Abdullah University of Science and Technology (KAUST) KAUST Catalysis Center (KCC), Thuwal 23955-6900, Saudi Arabia
- Institute of Organic Chemistry, RWTH Aachen University, Landoltweg 1, Aachen 52074, Germany
| |
Collapse
|
8
|
Seo CSG, Morris RH. Catalytic Homogeneous Asymmetric Hydrogenation: Successes and Opportunities. Organometallics 2018. [DOI: 10.1021/acs.organomet.8b00774] [Citation(s) in RCA: 135] [Impact Index Per Article: 22.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Chris S. G. Seo
- Department of Chemistry, University of Toronto, M5S3H6 Toronto, Ontario, Canada
| | - Robert H. Morris
- Department of Chemistry, University of Toronto, M5S3H6 Toronto, Ontario, Canada
| |
Collapse
|
9
|
Hayler JD, Leahy DK, Simmons EM. A Pharmaceutical Industry Perspective on Sustainable Metal Catalysis. Organometallics 2018. [DOI: 10.1021/acs.organomet.8b00566] [Citation(s) in RCA: 147] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- John D. Hayler
- API Chemistry, GlaxoSmithKline Medicines Research Centre, Stevenage, Hertfordshire SG1 2NY, United Kingdom
| | - David K. Leahy
- Process Chemistry, Takeda Pharmaceuticals International, Cambridge, Massachusetts 02139, United States
| | - Eric M. Simmons
- Chemical & Synthetic Development, Bristol-Myers Squibb Company, 1 Squibb Drive, New Brunswick, New Jersey 08903, United States
| |
Collapse
|
10
|
Wender PA, Ebner C, Fennell BD, Inagaki F, Schröder B. Ynol Ethers as Ketene Equivalents in Rhodium-Catalyzed Intermolecular [5 + 2] Cycloaddition Reactions. Org Lett 2017; 19:5810-5813. [PMID: 29034684 PMCID: PMC5833981 DOI: 10.1021/acs.orglett.7b02765] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The previously unexplored metal-catalyzed [5 + 2] cycloadditions of vinylcyclopropanes (VCPs) and electron-rich alkynes (ynol ethers) have been found to provide a highly efficient, direct route to dioxygenated seven-membered rings, a common feature of numerous natural and non-natural targets and building blocks for synthesis. The reactions proceed in high yield at room temperature and tolerate a broad range of functionalities. Substituted VCPs were found to react with high regioselectivity.
Collapse
Affiliation(s)
- Paul A. Wender
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Christian Ebner
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | - Brandon D. Fennell
- Departments of Chemistry and Chemical and Systems Biology, Stanford University, Stanford, California 94305, United States
| | | | | |
Collapse
|
11
|
Affiliation(s)
- Qi Huang
- Laboratoire de Synthèse
Organique, CNRS UMR 7652 Ecole Polytechnique, Palaiseau 91128 Cedex, France
| | - Samir Z. Zard
- Laboratoire de Synthèse
Organique, CNRS UMR 7652 Ecole Polytechnique, Palaiseau 91128 Cedex, France
| |
Collapse
|
12
|
Selekman JA, Qiu J, Tran K, Stevens J, Rosso V, Simmons E, Xiao Y, Janey J. High-Throughput Automation in Chemical Process Development. Annu Rev Chem Biomol Eng 2017; 8:525-547. [DOI: 10.1146/annurev-chembioeng-060816-101411] [Citation(s) in RCA: 59] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Joshua A. Selekman
- Chemical and Synthetic Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903;, , , , , , ,
| | - Jun Qiu
- Chemical and Synthetic Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903;, , , , , , ,
| | - Kristy Tran
- Chemical and Synthetic Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903;, , , , , , ,
| | - Jason Stevens
- Chemical and Synthetic Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903;, , , , , , ,
| | - Victor Rosso
- Chemical and Synthetic Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903;, , , , , , ,
| | - Eric Simmons
- Chemical and Synthetic Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903;, , , , , , ,
| | - Yi Xiao
- Chemical and Synthetic Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903;, , , , , , ,
| | - Jacob Janey
- Chemical and Synthetic Development, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903;, , , , , , ,
| |
Collapse
|
13
|
Luo G, Chen L, Conway CM, Kostich W, Johnson BM, Ng A, Macor JE, Dubowchik GM. Asymmetric Synthesis of the Major Metabolite of a Calcitonin Gene-Related Peptide Receptor Antagonist and Mechanism of Epoxide Hydrogenolysis. J Org Chem 2017; 82:3710-3720. [PMID: 28306261 DOI: 10.1021/acs.joc.7b00052] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
An asymmetric synthesis of the major metabolite of the calcitonin gene-related peptide recepotor antagonist BMS-846372 is presented. The variously substituted cyclohepta[b]pyridine ring system represents an underexplored ring system and showed some unexpected chemistry. Reactivities of epoxide and ketone functional groups on the cycloheptane ring were extensively controlled by a remote bulky TIPS group. The rate difference of the hydrogenolysis between two diastereomeric epoxide intermediates shed some light on the mechanism of epoxide hydrogenolysis, and further, deuterium labeling studies revealed more mechanistic details on this well-known chemical transformation for the first time.
Collapse
Affiliation(s)
- Guanglin Luo
- Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06443, United States
| | - Ling Chen
- Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06443, United States
| | - Charles M Conway
- Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06443, United States
| | - Walter Kostich
- Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06443, United States
| | - Benjamin M Johnson
- Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06443, United States
| | - Alicia Ng
- Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06443, United States
| | - John E Macor
- Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06443, United States
| | - Gene M Dubowchik
- Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06443, United States
| |
Collapse
|
14
|
Luo G, Chen L, Conway CM, Kostich W, Macor JE, Dubowchik GM. Asymmetric Synthesis of Heterocyclic Analogues of a CGRP Receptor Antagonist for Treating Migraine. Org Lett 2015; 17:5982-5. [PMID: 26650258 DOI: 10.1021/acs.orglett.5b02921] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Guanglin Luo
- Bristol-Myers Squibb
Research & Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Ling Chen
- Bristol-Myers Squibb
Research & Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Charles M. Conway
- Bristol-Myers Squibb
Research & Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Walter Kostich
- Bristol-Myers Squibb
Research & Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - John E. Macor
- Bristol-Myers Squibb
Research & Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| | - Gene M. Dubowchik
- Bristol-Myers Squibb
Research & Development, 5 Research
Parkway, Wallingford, Connecticut 06492, United States
| |
Collapse
|
15
|
Yang H, Huo N, Yang P, Pei H, Lv H, Zhang X. Rhodium Catalyzed Asymmetric Hydrogenation of 2-Pyridine Ketones. Org Lett 2015; 17:4144-7. [DOI: 10.1021/acs.orglett.5b01878] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Hailong Yang
- Key Laboratory of Biomedical Polymers of Ministry of Education & College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei 430072, China
| | - Ningning Huo
- Key Laboratory of Biomedical Polymers of Ministry of Education & College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei 430072, China
| | - Ping Yang
- Key Laboratory of Biomedical Polymers of Ministry of Education & College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei 430072, China
| | - Hao Pei
- Key Laboratory of Biomedical Polymers of Ministry of Education & College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei 430072, China
| | - Hui Lv
- Key Laboratory of Biomedical Polymers of Ministry of Education & College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei 430072, China
| | - Xumu Zhang
- Key Laboratory of Biomedical Polymers of Ministry of Education & College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei 430072, China
| |
Collapse
|
16
|
Sivanandan ST, Shaji A, Ibnusaud I, Seechurn CCCJ, Colacot TJ. Palladium-Catalyzed α-Arylation Reactions in Total Synthesis. European J Org Chem 2014. [DOI: 10.1002/ejoc.201403301] [Citation(s) in RCA: 85] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
17
|
Development of a scalable palladium-catalyzed α-arylation process for the synthesis of a CGRP antagonist. Tetrahedron 2013. [DOI: 10.1016/j.tet.2013.04.057] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
18
|
Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, Kostich W, Lentz KA, Santone KS, Schartman R, Browning M, Tong G, Houston JG, Dubowchik GM, Macor JE. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. J Med Chem 2012; 55:10644-51. [PMID: 23153230 DOI: 10.1021/jm3013147] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated clinical efficacy in the treatment of acute migraine. Herein, we describe the design, synthesis, and preclinical characterization of a highly potent, oral CGRP receptor antagonist BMS-927711 (8). Compound 8 has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical properties, and shows dose-dependent activity in a primate model of CGRP-induced facial blood flow. Compound 8 is presently in phase II clinical trials.
Collapse
Affiliation(s)
- Guanglin Luo
- Molecular Sciences and Candidate Optimization, Disease Sciences and Biologics, Bristol-Myers Squibb Research & Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|